JPWO2021186056A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021186056A5 JPWO2021186056A5 JP2022555951A JP2022555951A JPWO2021186056A5 JP WO2021186056 A5 JPWO2021186056 A5 JP WO2021186056A5 JP 2022555951 A JP2022555951 A JP 2022555951A JP 2022555951 A JP2022555951 A JP 2022555951A JP WO2021186056 A5 JPWO2021186056 A5 JP WO2021186056A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence seq
- seq
- sequence
- lcvr
- hcvr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 15
- 239000000427 antigen Substances 0.000 claims 14
- 108091007433 antigens Proteins 0.000 claims 14
- 102000036639 antigens Human genes 0.000 claims 14
- 239000012634 fragment Substances 0.000 claims 14
- 210000003289 regulatory T cell Anatomy 0.000 claims 7
- 210000002865 immune cell Anatomy 0.000 claims 5
- 230000011664 signaling Effects 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000004068 intracellular signaling Effects 0.000 claims 3
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 101100166600 Homo sapiens CD28 gene Proteins 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical group COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000006058 immune tolerance Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 210000000581 natural killer T-cell Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20305298.0 | 2020-03-20 | ||
EP20305298 | 2020-03-20 | ||
PCT/EP2021/057132 WO2021186056A1 (en) | 2020-03-20 | 2021-03-19 | Chimeric antigen receptor specific for human cd45rc and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023518538A JP2023518538A (ja) | 2023-05-02 |
JPWO2021186056A5 true JPWO2021186056A5 (zh) | 2024-03-27 |
Family
ID=71465223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022555951A Pending JP2023518538A (ja) | 2020-03-20 | 2021-03-19 | ヒトcd45rcに特異的なキメラ抗原受容体およびその使用 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230147657A1 (zh) |
EP (1) | EP4121457A1 (zh) |
JP (1) | JP2023518538A (zh) |
KR (1) | KR20230004510A (zh) |
CN (1) | CN115916823A (zh) |
AU (1) | AU2021237790A1 (zh) |
BR (1) | BR112022018795A2 (zh) |
CA (1) | CA3172120A1 (zh) |
IL (1) | IL296546A (zh) |
MX (1) | MX2022011683A (zh) |
WO (1) | WO2021186056A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230032871A1 (en) * | 2021-07-14 | 2023-02-02 | Innovative Cellular Therapeutics Holdings, Ltd. | Recombinant Viral Particle for Gene and/or Cellular Therapy |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
ES2165851T3 (es) | 1991-11-25 | 2002-04-01 | Enzon Inc | Proteinas multivalentes que se unen a antigenos. |
US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
WO1998056915A2 (en) | 1997-06-12 | 1998-12-17 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
AU1086501A (en) | 1999-10-15 | 2001-04-30 | Carnegie Institution Of Washington | Rna interference pathway genes as tools for targeted genetic interference |
US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
AU2001243288B2 (en) | 2000-02-24 | 2005-11-24 | Life Technologies Corporation | Simultaneous stimulation and concentration of cells |
AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
WO2004094642A2 (en) | 2003-04-24 | 2004-11-04 | Fondazione Centro San Raffaele Del Monte Tabor | Lentiviral vectors carrying synthetic bi-directional promoters and uses thereof |
EP3363907A1 (en) | 2004-05-27 | 2018-08-22 | The Trustees of the University of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
US20070036773A1 (en) | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
EP1929073A4 (en) | 2005-09-27 | 2010-03-10 | Amunix Inc | PROTEIN MEDICAMENT AND ITS USE |
GB0603081D0 (en) | 2006-02-15 | 2006-03-29 | Dynal Biotech Asa Oslo | Method |
US9181527B2 (en) | 2009-10-29 | 2015-11-10 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
EP2596011B1 (en) | 2010-07-21 | 2018-10-03 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of a hla locus |
CA2832540C (en) | 2011-04-08 | 2020-09-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer |
DK3401400T3 (da) | 2012-05-25 | 2019-06-03 | Univ California | Fremgangsmåder og sammensætninger til rna-styret mål-dna-modifikation og til rna-styret transskriptionsmodulering |
WO2014093595A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
KR20150105634A (ko) | 2012-12-12 | 2015-09-17 | 더 브로드 인스티튜트, 인코퍼레이티드 | 서열 조작을 위한 개선된 시스템, 방법 및 효소 조성물의 유전자 조작 및 최적화 |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
JP6692343B2 (ja) | 2014-08-01 | 2020-05-13 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 薬物としての使用のための抗cd45rc抗体 |
JP2019513347A (ja) * | 2016-03-04 | 2019-05-30 | ノバルティス アーゲー | 複数のキメラ抗原受容体(car)分子を発現する細胞およびその使用 |
EP3652306A1 (en) * | 2017-07-13 | 2020-05-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for increasing expansion and immunosuppressive capacity of a population of cd8+cd45rclow/-tregs |
EP3498293A1 (en) | 2017-12-15 | 2019-06-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Treatment of monogenic diseases with an anti-cd45rc antibody |
EP3626265A1 (en) * | 2018-09-21 | 2020-03-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-human cd45rc antibodies and uses thereof |
-
2021
- 2021-03-19 AU AU2021237790A patent/AU2021237790A1/en active Pending
- 2021-03-19 US US17/912,726 patent/US20230147657A1/en active Pending
- 2021-03-19 JP JP2022555951A patent/JP2023518538A/ja active Pending
- 2021-03-19 MX MX2022011683A patent/MX2022011683A/es unknown
- 2021-03-19 IL IL296546A patent/IL296546A/en unknown
- 2021-03-19 KR KR1020227036234A patent/KR20230004510A/ko active Search and Examination
- 2021-03-19 CN CN202180036571.9A patent/CN115916823A/zh active Pending
- 2021-03-19 BR BR112022018795A patent/BR112022018795A2/pt unknown
- 2021-03-19 CA CA3172120A patent/CA3172120A1/en active Pending
- 2021-03-19 WO PCT/EP2021/057132 patent/WO2021186056A1/en active Application Filing
- 2021-03-19 EP EP21712190.4A patent/EP4121457A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210009688A1 (en) | Anti-pd-1 antibody and use thereof | |
AU2009224690B2 (en) | Agent for treating disease | |
US9334325B2 (en) | Method for treating psoriasis | |
US7524498B2 (en) | Human immunomodulatory monoclonal antibodies for the treatment of cancer | |
US7829086B2 (en) | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease | |
US8664363B2 (en) | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease | |
CA2819520C (en) | Anti cd4 antibodies to prevent in particular graft-versus-host-disease (gvhd) | |
JP2020528768A5 (zh) | ||
AU2016359683A1 (en) | Heterodimeric antibodies that bind CD3 and CD38 | |
JP2016513467A5 (zh) | ||
WO2022089353A1 (zh) | 靶向bcma的单域抗体及其用途 | |
KR20160044063A (ko) | 항-pd1 항체 및 이의 치료 및 진단 용도 | |
JP2014532074A5 (zh) | ||
US20240101668A1 (en) | Polypeptides and their use in treatment of disease | |
JPWO2021186056A5 (zh) | ||
WO2024017362A1 (zh) | 靶向gprc5d和/或bcma的嵌合抗原受体及其应用 | |
CN116789820A (zh) | 一种新型免疫调节剂的开发和应用 | |
EP4247940A1 (en) | Depleting monoclonal antibodies against natural killer cells | |
JPWO2021163389A5 (zh) | ||
WO2019072274A1 (zh) | 一种激动型4-1bb单克隆抗体 | |
JPWO2020006568A5 (zh) |